Global Prevalence And Clinical Trials Landscape Of Acute Myeloid Leukaemia

Acute Myeloid Leukaemia (AML) is a malignancy of the blood characterized by the abnormal growth of myeloid cells, predominantly affecting adults. Despite advancements in treatment, AML remains challenging to manage, with low survival rates. Various risk factors, such as age and genetic predisposition, contribute to its development.

The current standard of care for AML involves a combination of chemotherapy and targeted drugs. However, ongoing research is delving into the molecular mechanisms underlying AML, with the aim of developing personalized therapies tailored to individual patients.

This FAQ delves into the latest advancements in AML treatment, focusing on innovative drugs and ongoing clinical trials. By exploring these developments, we aim to shed light on the potential impact on patient outcomes and the future of AML management.